Hybrid Nanosystems for Anticancer Therapy
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Nanomedicine and Nanotechnology".
Deadline for manuscript submissions: 20 March 2025 | Viewed by 97
Special Issue Editor
Interests: materials chemistry; cancer theranostics; nanomedicine
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Hybrid nanostructures for cancer therapy are innovative platforms that integrate the advantages of nanomaterials and therapeutic agents to enhance cancer treatment. These nanostructures combine the unique properties of various materials, such as metals, polymers, and biomolecules, to achieve multifunctionality in diagnosis and therapy. On the one hand, hybrid nanostructures can improve the delivery and targeting of anticancer drugs, increasing their efficacy while reducing side effects. On the other hand, they can also facilitate synergistic therapies, such as combining photothermal therapy with chemotherapy, to induce more effective cancer cell destruction. Moreover, the nanostructures’ ability to incorporate imaging agents enables simultaneous diagnosis and treatment, known as theranostics. Despite these promising features, challenges remain, including the complexity of the design and potential toxicity. Nonetheless, hybrid nanostructures represent a versatile and promising approach to overcoming current limitations in cancer therapy, offering a new direction for more effective treatments.
This Special Issue aims to collect recent research in the design and preparation of hybrid nanostructures and focuses on the use of them in biomedical fields, especially for anti-cancer treatment.
We look forward to receiving your contributions.
Dr. Deblin Jana
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- hybrid nanoparticles
- targeted therapy
- anti-cancer treatment
- drug delivery
- cancer immunotherapy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
